Drug
Aav5 Rpgr
Aav5 Rpgr: highest development phase Phase 1/2, developed by MeiraGTx. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- MeiraGTx
Trials
| Drug | Phase | Indication |
|---|---|---|
| AAV5-RPGR NCT03252847 | Phase 1/2 | X-Linked Retinitis Pigmentosa |
Latest
No recent events.
Follow Aav5 Rpgr on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.